Off-Label Opioid Promotion: US FDA ‘Does Not Object’ To Intranasal Deterrence Data, Egalet Says

In decision that reflects policy confluence of opioid abuse deterrence, off-label communications and marketing exclusivity, FDA will allow Egalet to distribute truthful, nonmisleading information about Arymo ER's intranasal abuse-deterrence data even though the long-acting opioid was blocked from receiving a labeling claim.

Opioid abuse epidemic concept

The US FDA's approval of Egalet Corp.’s Arymo ER (morphine sulfate extended-release) has led to a collision of legal, regulatory and public health policies around the high-profile issues of opioid abuse, off-label promotion and market exclusivity incentives.

The agency appears to have opted for a permissive approach on one of the three prongs to address a public...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Marketing & Advertising

More from Compliance